drugset / Trial / NCT02549404
Phase 3 Study of KHK7580
NaSingle-groupOpen-labelTreatment
Summary
This long-term study is designed to evaluate safety and efficacy of KHK7580 orally administered once daily for 52 weeks for patients with secondary hyperparathyroidism receiving hemodialysis.
Timeline
- Start
- 2015-09-28
- Primary completion
- 2016-12-06
- Completion
- 2016-12-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EVOCALCET | Small molecule | — | Oral |